Compare CTY & JFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTY | JFR |
|---|---|---|
| Founded | 2023 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2026 | 2004 |
| Metric | CTY | JFR |
|---|---|---|
| Price | $17.55 | $7.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $37.33 | N/A |
| AVG Volume (30 Days) | 250.4K | ★ 724.9K |
| Earning Date | 12-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.31% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $62.96 | N/A |
| Revenue Next Year | $7.47 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.81 | $7.07 |
| 52 Week High | $22.65 | $8.00 |
| Indicator | CTY | JFR |
|---|---|---|
| Relative Strength Index (RSI) | 41.04 | 37.49 |
| Support Level | $16.12 | $7.09 |
| Resistance Level | $21.98 | $7.45 |
| Average True Range (ATR) | 2.35 | 0.08 |
| MACD | -0.15 | -0.01 |
| Stochastic Oscillator | 25.44 | 9.09 |
City Therapeutics Inc is a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. Its current pipeline is focused on indications with unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (Stargardt disease), and anemia of chronic disease.
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income. The fund invests the majority of its managed assets in secured senior loans and unsecured senior loans, which unsecured senior Loans are generally, at the time of investment, investment grade quality.